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Abstract: The problem of drug resistance is very worrying and ever increasing. Resistance is due not
only to the reckless use of antibiotics but also to the fact that pathogens are able to adapt to di↵erent
conditions and develop self-defense mechanisms such as living in biofilms; altogether these issues
make the search for alternative drugs a real challenge. Antimicrobial peptides appear as promising
alternatives but they have disadvantages that do not make them easily applicable in the medical
field; thus many researches look for solutions to overcome the disadvantages and ensure that the
advantages can be exploited. This review describes the biofilm characteristics and identifies the
key features that antimicrobial peptides should have. Recalcitrant bacterial infections caused by the
most obstinate bacterial species should be treated with a strategy to combine conventional peptides
functionalized with nano-tools. This approach could e↵ectively disrupt high density infections
caused by biofilms. Moreover, the importance of using in vivo non mammalian models for biofilm
studies is described. In particular, here we analyze the use of amphibians as a model to substitute the
rodent model.
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1. Introduction
The growing number of nosocomial infections associated to the emergence of microorganisms
resistant to conventional antibiotics has been recognized as one of the major concerns a↵ecting
modern healthcare.
It has been estimated that less than 0.1% of the total microbial population is in the planktonic
mode of growth (isolated bacteria cells). Instead, the majority of the bacteria are organized in more
complex structures known as biofilms. Accordingly, more than 80% of all bacterial infections are due
to microorganisms in their biofilm mode of growth [1].
Biofilms can form in any host tissue causing pulmonary infections in patients with cystic fibrosis,
infections in diabetic patients, recurrent urinary tract infections, or colonization of abiotic surfaces
such as central venous or urinary catheters, heart valves, intrauterine devices, and dental implants.
Formation of biofilms is not the only aspect responsible of chronic infections, which are di cult to
diagnose and treat with conventional antibiotic treatments, but also current antimicrobial therapy
practices have produced a rapid growth of drug-resistant infections [2,3]. Moreover, mass use (both for
humans and animals) and easy access of the antibiotics has led to further development of resistance,
making the problem even more serious for our society from both an economical and health perspective.
In their biofilm form, bacteria adhere on a surface and grow while being surrounded by a
self-produced matrix of extracellular polymeric substances (EPS) such as polysaccharides, proteins,
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and extracellular DNA (eDNA) that protect biofilm inhabitants against the host immune system and
antimicrobial treatments [2,4].
Defeating bacteria within the biofilmmatrix is challenging not only because thematrix functions as
a protecting screen but also because bacteria assume a dormant state (persisters) which can significantly
compromise the e cacy of currently available antibiotics, since their mechanisms of action interfere
with bacterial metabolism or proliferation. In their biofilm state, bacteria can also be resistant towards
the host’s innate and adaptive immune and inflammatory defense systems. Hence, a global interest is
directed towards the need to solve the problem of bacterial resistance.
Biofilms are less susceptible to antimicrobial treatment and to the host immune system than
planktonic cells, thus it could be important to develop an ideal strategy to combat chronic biofilm
related infections strengthening the search for new antimicrobials.
2. Understanding Biofilm Properties
Properties of biofilm lifestyle have to be considered when peptide strategies are proposed for the
prevention of its formation or in general to design promising anti-biofilm agents. Biofilms develop in
three phases: initial adhesion, maturation, and dispersion. The first phase is mediated by some host
molecules such as albumin, lipids, complements, fibronectins, and by the interactions of some bacterial
surface structures such as pili, fimbriae, but is also influenced by the environment, the micro-organisms
properties, the material surfaces, and the flow conditions [5,6].
The maturation is especially associated with the EPS production, which allows the stabilization
of the biofilm. The last phase, the dispersion, corresponds to the release of cells that colonize new
sites. Mature biofilms change microenvironment conditions such as pH, oxygen level, and weaken
the activity of antibiotics as well as create particular conditions to induce the state of dormant and
non-dividing cells called “persisters” that are believed to play an important role in resistance.
The formation of P. aeruginosa biofilms is very frequent in patients with cystic fibrosis, while
S. aureus is frequently correlated with wounds and the multi-species biofilms with urinary catheter or
cardiovascular devices.
Recently, it has been reported that the diseases caused by Candida albicans and non-albicans Candida
(NAC) spp., such as C. glabrata, C. tropicalis, C. krusei, C. dubliensis, or C. parapsilosis are associated with
biofilm growth and, in late stages, their biofilms are more resistant to antifungal drugs. Candida biofilm
formation is characterized by three development phases which are the early adhesion phase (0–11 h),
intermediate phase (12–30 h), and maturation phase (31–72 h). In order to colonize and form biofilms,
cells must attach to the surface or host cells becoming more resistant; new formulations, new agents,
and combination therapies are urgently needed to prevent adherence and biofilm development [7].
An e↵ective anti-biofilm agent should act in di↵erent environmental niches in order to reach cells
in di↵erent growth rate, and also persisters. For very resistant biofilms, a combination of an agent
acting on metabolic active cells and another one able to act on persisters could represent a valid strategy.
EPS is the major component of biofilms; it produces an appropriate environment for the bacteria,
favors the adhesion cell-to-cell and cell-to-surface but also constitutes a barrier that interferes with the
action of antimicrobial agents decreasing their bioactive concentrations. Therefore, good anti-biofilm
agents should be able to penetrate the matrix or inhibit the accumulation on the surface. As cells in
biofilms can communicate through secretion of molecules known as auto-inducers that control the
quorum sensing (QS), a promising anti-biofilm agent could interfere with QS signals favoring biofilm
inhibition or dispersion.
A drug that exhibits all these anti-biofilm properties together is still not available, even if many
studies are devoted to design antimicrobial peptides (AMPs) which can display a combination of these
features [8,9].
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3. Antimicrobial Peptides as Anti-Biofilm Agents
Antimicrobial peptides [10–13] are a promising class of compounds, widely distributed in nature,
mainly as a part of innate immunity of organisms and are currently receiving considerable attention as
a potential alternative to conventional antibiotics to prevent and treat bacterial infections [3].
They have a broad spectrum activity against many microbes ranging from viruses to parasites,
and are also less susceptible to evolved antibacterial resistance because of their fast mechanism of action,
rapid protease digestion with low bioavailability, and peptide aggregation [14]. Moreover, they exhibit
a low probability to develop antimicrobial resistance likely thanks to their membrane-associated
activity. Many AMPs are positively charged, amphiphilic molecules that kill bacteria through
membrane disruption and/or pore formation, but also other modes of action are envisioned, such as
penetration into the bacterial cytoplasm and inhibition of proteins, cell wall, or enzymes synthesis [15].
Many studies also showed that AMPs are e↵ective against multi-drug resistant bacteria and fungi
not only because they act disrupting membranes due to the electrostatic negatively charged bacterial
surfaces, but also interfering with metabolic processes such as inhibition of cell wall, nucleic acid or
protein biosynthesis rendering more di cult for microorganism to develop resistance.
However, positive charges although being essential for antimicrobial action also represent an
impediment to AMPs penetration into biofilms [16]. The main reason lies in the fact that polysaccharide
(EPS) of the biofilm matrix is negatively charged and can trap positive AMPs preventing them
from displaying their action against bacteria. Moreover, many AMPs are subject to hydrolytic and
proteolytic breakdown.
Several studies have described AMPs and how to modify their sequence in order to obtain novel
antibiofilm agents with increased activity and proteolytic stability. Among them, LL-37 has shown an
activity against S. aureus bacteria as well as in preventing action against biofilm formation. However,
despite the high potency of this peptide, the use of LL-37 is limited because of its poor stability; indeed,
it is easily cleaved by endogenous enzymes highly present in the gut (trypsin and pepsin), pancreas
(elastace) and serum (plasmin). Further, also enzymes secreted by microorganisms including S. aureus
(aureolysin, V8 protease) have shown the ability to cleave LL-37. Another disadvantage is associated
with non-specific cytotoxicity (e.g., leukocyte, T-cell, and red blood cell viability). Shorter derivatives of
LL-37 can overcome some of these limitations by improving stability, reducing toxicities, and lowering
production costs [17–23]. de la Fuente-Nunez et al. [24] identified the short cationic peptide 1037 with
a weak antimicrobial activity on Gram-positive and Gram-negative bacteria but with a good anti-
biofilm activity with death of cells. Moreover, they showed a decreased expression of a variety of
genes involved in biofilm formation for P. aeruginosa.
In a recent study, de Alteriis at al. demonstrated that a membrane-penetrating peptide gH625
and its analogue gH625-GCGKKKK were e↵ective both on planktonic cells and C. tropicalis/Serratia
marcenscens and C. tropicalis/S. aureus polymicrobial biofilms [25]. They showed an eradication
activity stronger for the modified analogue, also at concentration lower than their minimal inhibitory
concentration (MIC) on planktonic cells.
Many AMPs and peptido-mimetics present an action against microbial biofilms. They act in the
first phase of biofilm formation and display a preventive action, or disperse existing ones, reduce
biomass or kill microbial cells within biofilms as schematized in Figure 1. Some peptides perform
di↵erent antimicrobial actions according to the concentration; for instance, at certain concentrations
they are able to limit biofilm formation without a↵ecting planktonic growth of the bacteria [26].
In vivo studies demonstrated that biofilms are also capable of escaping host immune responses
leading to an intense host pro-inflammatory response, which contributes to tissue damage and a lower
action of macrophages [27]. Another required property for anti-biofilm agents is the capability of
balancing the pro-inflammatory and anti-inflammatory immune cell responses.
AMPs can be divided mainly into two groups: natural and synthetic. Natural AMPs are part of
the natural anti-inflammatory and antimicrobial system and display a synergistic e↵ect with antibiotics;
they represent a source of inspiration for the design of synthetic AMPs and their main disadvantage
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is the high instability due to the rapid degradation and easy cleavage by proteases. To increase
the potential of therapeutic applications of AMPs, novel chemically modified analogues have been
synthetized to enhance their pharmacological properties [28–31].Pharmaceutics 2019, 11, x 4 of 15 
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Most AMPs are toxic to bacteria but not to eukaryotes owing to the di↵erent membrane
organization of bacteria and multicellular organisms [23,32]. Moreover, they present di↵erent and
faster killing mechanisms compared to conventional antibiotics because exploiting the disruption and
permeabilization of microbial cell membranes.
Among natural AMPs, those derived from amphibians certainly hold great promise; in fact,
the amphibians present a surprisingly diverse population of antimicrobial peptides [33]. New AMPs
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are isolated from amphibian secretions, which are mainly produced in their skin granular glands and
are released following stress or injury [34,35].They have received great attention in recent years and as
a matter of fact, more than a thousand of amphibian peptides are deposited in Antimicrobial Peptide
Database [36–38]. Because their innate resistance to bacterial infections the amphibians have been
studied since the 1930s [39] and in 1987, for the first time, Zaslo↵ extracted two potent nonhemolytic
antimicrobial peptides from X. laevis skin [40]. AMPs are frequently isolated from amphibians as a
mold to produce synthetic analogues to fight biofilms.
Here we list some amphibian AMPs isolated in recent years.
Li et al. [41] isolated a small anionic antibacterial peptide from X. laevis secrections (XLAsp-P1).
XLAsp-P1 showed high activity in vitro against a great number of Gram-positive and Gram-negative
bacteria with MIC starting at 10 µg/mL. Moreover, it shows only 6.2% of hemolytic activity when used
at 64 µg/mL. This peptide acts on the membrane.
Wu et al. [42] used the skin secretion of Litoria infrafrenata to discover peptides with therapeutic
potential; they cloned a frenatin gene and identified the peptide frenatin 4.1 and a post-translation
modified peptide, frenatin 4.2. Moreover, they designed analogues that exhibited enhanced
antimicrobial activities as frenatin 4.2a.
Huang et al. [43] extracted from the mucus of Phyllomedusa hypochondrialis, Dermaseptin-PH,
and investigated its antimicrobial activity. Dermaseptin-PH inhibited the growthof bothGram-negative
and Gram-positive bacteria and of C. albicans. Liu et al. [44] showed that phylloseptin-PTa and
phylloseptin-PHa isolated from Phyllomedusa tarsius and Phyllomedusa hypochondrialis have antimicrobial
activities against Gram-positive bacteria (such as Staphylococcus aureus and Enterococcus faecalis) and
methicillin-resistant Staphylococcus aureus.
Sang et al. [45] have extracted from the secretion of Pelophylax kl. esculentus skin the temporin-PE,
a potentAMP (Table 1). Modifications of this peptide introducing short sequences, as TAT, at C-terminus
or modifications of FLP motif produced variations of its activity.
Table 1. Schematic representation of some AMP extracted by amphibian.
Amphibian AMPs Production
Species Family Peptide E↵ects Pathogens
X. laevis pipidae XLAsp-P1 haemolytic activity,destruction of the membrane
Gram-positive and
Gram-negative
L. infrafrenata Hylidae frenatin 4.1 frenatin 4.2.frenatin 4.2a antimicrobial activities all bacteria tested
P. hypochondrialis Hylidae Dermaseptin-PH inhibition of the growth Gram-negative andGram-positive Candida albicans
P. tarsius
P. hypochondrialis Hylidae
phylloseptin-PTa and
phylloseptin-PHa antimicrobial activities S. aureus, E. faecalis
P. kl. esculentus Ranidae temporin-PE antimicrobial activities antimicrobial activities
A. davidianus Cryptobranchidae andricin B antimicrobial activities all bacteria tested and somefungi Staphylococcus aureus
L. fujianensis Dicroglossidae Japonicin-2LF membrane permeabilization S. aureus and MRSA
Pei et al. [46] isolated andricin B from the blood of A. davidianus by a new method which
implied the magnetic liposome adsorption combined with reversed-phase high-performance liquid
chromatography. Andricin B is active against all bacteria tested and some fungi. The MICs were in the
range 8–64 µg/mL. Moreover, the hemolytic tests indicated that andricin B is safe at the MICs at which
it inhibits the growth of S. aureus.
Yuan et al. [47] isolated Japonicin-2LF from the skin mucus of Limnonectes fujianensis through the
combination of cDNA cloning and MS/MS sequencing. The activity of this peptide was evaluated
with di↵erent methods. They used the Galleria mellonella infection model to assess the e cacy of
Japonicin-2LF. This peptide showed great antimicrobial activity against S. aureus and MRSA, killing
the bacteria via membrane permeabilization. Japonicin-2LF acts through inhibition and removal of
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biofilms, especially against MRSA biofilm. In vivo studies indicated that Japonicin-2LF is a potential
candidate to control the MRSA infection in cystic fibrosis patients.
Most anti-biofilm peptides work at concentrations equal or higher than their MIC but there are
some peptides that showed their action also at concentration much lower than MIC interfering with
the biofilm life-style and displaying that the optimal antimicrobial activity against planktonic cells
does not necessarily coincide with an optimal anti-biofilm e↵ect. In other words, anti-biofilm activity
is not necessarily correlated to antimicrobial activity.
Generally, the minimal biofilm inhibiting concentration (MBIC) of AMPs is much lower than
minimal inhibitory concentration of bacterial growth (MIC). Sometimes they prevent the intracellular
accumulation of secondary messenger nucleotide molecules (ppGpp, c-d-GMP) which are involved
in many metabolic steps such as colonization, adhesion, and communication in Gram-positive and
Gram-negative bacteria [14]. Extracellular DNA (e-DNA) is a major component of bacteria and fungi
biofilm. It is known that in biofilm e-DNA acts as intracellular connector to maintain the biofilm
architecture, but it is also known that it may favor the exchange of a pool of genes interested in
acquisition of virulence or resistance in bacteria forming biofilm, its release is under control of QS
signals, and, finally, it could be a nutrient source or a cation chelator. Consequently, a possible
anti-biofilm strategy could be directed on e-DNA composition.
Moreover, EPS also plays an essential role in biofilm life-style allowing the initial colonization
and the accumulation of nutrients and stabilization of enzymes. It has been demonstrated that EPS
promotes the self-association of cationic peptides allowing a better interaction with membrane bilayers
but, on the other side, EPS entraps AMPs before they can reach bacterial targets so that they constitute
a protective environment against the innate host defense during an infection [26,48]. For a better
strategy, a good anti-biofilm peptide should carry the right balance between antimicrobial activity and
EPS permeability.
Despite their promising properties, AMPs are not used in clinical settings because of their
potential toxicity at e cacious doses, instability in human fluids, as well as ecological toxicity, which is
under analysis.
4. Nanoparticles Coated with AMPs
Nanotechnology through the combination of AMPs and nanoparticles (NPs) could improve the
antimicrobial action of the peptides but also overcome their disadvantages [49–51]. Nanotechnology
o↵ers a number of promising opportunities to develop antimicrobial nanosystems that break the
biofilm barrier and penetrate over significantly larger distances into biofilm, killing its microorganisms
more than conventional antibiotics or AMPs.
Both the multidrug resistance and protective character of biofilms could make common antibiotics
thousands-fold less potent. Despite the initial enthusiasm for AMPs as alternative candidates to
antibiotics, disadvantages have limited their development and clinical use. Thanks to nanotechnology,
many nanomaterials (1–100 nm) have been developed with powerful capability of delivering
drugs. Among them, NPs are widely exploited in di↵erent fields. According to the application,
the NP composition can vary and for biomedical applications, various biocompatible materials have
been exploited. Many NPs have been demonstrated to have anti-biofilm activities by themselves,
but nonetheless, they can carry antimicrobial agents such as AMPs and show enhanced properties.
Silver NPs, gold NPs, quantum dots (QD) NPs have anti-biofilm activities even though their
toxicity remain a serious issue which prevents their full application.
Functionalization of NPs surface with AMPs is attracting growing interest for three main reasons:
(i) NPs can facilitate delivery; (ii) NPs make peptides more resistant towards degradation; (iii) peptides
form a protecting/coating shell on the NPs, which can reduce their toxic e↵ect. Thus, when conjugated,
peptides and NPs combine the antimicrobial activity of both components and are also able to overcome
their drawbacks. Thus, functionalization of NPs with AMPs might represent a novel approach to
overcome some problems related to the limited clinical use of AMPs, as reported in Figure 2.
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Figure 2. Coating of nanoparticles with antimicrobial peptides is a promising strategy to overcome the
drawbacks of the nanoparticles and peptides themselves and improve their action with a synergistic
e↵ect. Moreover, the conjugation may a↵ect the peptide properties and the design of new antimicrobial
nanomaterials is required.
Covalent immobilization of AMPs and their analogues is widely exploited. Although being a
promising stra egy, c valen immobilization appea s to produce new prop rties and functions that are
not owned by th ir building blocks [52], which may influence their interaction with cell membranes
and their activity. As a conseque ce, the antimicrobial activity may be a↵ected b c use the charge
distribution will be d ↵erent from that of single peptide mole ules.
A novel trategy to dev lop na osystems c ated with AMPs is represented by the use of
self-assembl d pep ides f r the obtai ment of on dem n supramolecular nanostructures (nanotubes,
nanobelts, fibrils, nanovesicles, gels, and nanocages), which can isassemble upon co tact with th
bacteria and release the AMP. Recently, a novel v r atile platform was developed in our laboratory t
immobilize an analogue of the marine antimicrobial peptide myxinidin (WMR) on a peptide based
biomateri l [53]; the AMP sequence was located on the periphery of the nanofiber, an was able t
incr ase their e↵ect ve local concen ration compar d to soluble p ptides and was the driving force fo
improved antibacte ial activ ty [33,54–56]. The presence of WMR on self-assembled nanostructures
improved anti-biofilm activity against the Gram-negative bacterium P. aeruginosa and the fungus
C. albicans; th fibers w re ble th to inhibit the biofilm formation nd to erad cate pre-formed
biofilms [53,57].
Al aaytah et al. showed that RBRBR-CS-NPs, a polymeric NPs functionalized with RBRBR,
cationic ultrashort AMPs, were active against wild-type and the multidrug-resistant clinical
isolated strains f Gram-positive bacteria compared to the p ptide-unloaded nanoparticles [58].
The a timicrobial e↵ect s very powerful also against clinical isolates of the resistant st ains of S. aureus
compared to free RBRBR.
Boden et al. [59] studied a highly cationic peptide PuroA (FPVTWRWWKWWKG-NH2), derived
from the tryptophan-rich domain of wheat puro indoline proteins, chosen because of its broad
spectrum of antimicrobial activity [16]; the peptide was conjugated with a colloid BCC layer as a
suitable platform with inherent nano-/microstructures and topographies for covalent immobilization
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of AMPs. The results showed a substantial increase of the anti-biofilm properties of PuroA-modified
BCCs compared to the activity of unbound PuroA demonstrating also that changes in topography
a↵ect bacterial attachment profiles and growth.
To date, comprehensive studies of AuNPs on bacteria have rarely been carried out and very
little is known about the biological e↵ects of AuNPs conjugated to AMPs [60,61]. Casciaro et al.
identified a derivative of the frog skin AMP esculentin-1a, esculentin-1a(1-21)NH2[Esc(1-21)],
GIFSKLAGKKIKNLLISGLKG-NH2, corresponding to the first 20 residues of esculentin-1a, with
a strong activity against both free-living and sessile forms of either reference or clinical isolates of
P. aeruginosa [61]. Esc(1-21)-coated AuNPs were tested for their antibiofilm activity; when used against
the sessile form of P. aeruginosa, 50% of the biofilm cells was killed within 2 h treatment at a peptide
concentration of 0.171 M which was only two-fold higher than the MBC50, and about 17-fold lower
than the MBEC 50 of the free peptide. Therefore, the frog skin AMP esculentin-1a conjugated to
AuNPs via PEG linker, demonstrated a remarkably improved antibacterial activity compared to the
free peptide without being toxic to human cells. This is likely due to the significant quantity of Esc(1-21)
present on the surface of AuNPs@PEG, regardless of its orientation, and to the high concentration of
AuNPs@Esc(1-21) on the bacterial surface as well as to the prolonged peptide bioavailability, being less
accessible to bacterial proteases. The functionalized AuNPs@Esc(1-21) also presented a membrane
perturbing activity as a plausible mechanism of bacterial killing.
Galdiero et al. [62] reported that the antimicrobial activity of QDs is enhanced by the
functionalization with the antimicrobial peptide indolicidin (QDs-Ind) against S. aureus (ATCC 6538),
P. aeruginosa (ATCC 1025), E. coli (ATCC 11229), and Klebsiella pneumoniae (ATCC 10031), while the
ecotoxicity decreases compared to the QDs and indolicidin separately using an ecotoxicological battery
of test systems and indicators able to detect di↵erent e↵ects using a variety of end points [62].
de Alteriis et al. [63] studied the e cacy in vitro of a nanocomplex of AuNPs coated with
indolicidin (AuNPs–indolicidin) in both preventing cell adhesion and eradicating the developed
biofilms of some Candida clinical isolates and ATCC strains showing an enhanced indolicidin activity
likely related to an enhanced stability of the nano-complex towards protease degradation occurring in
the matrix and/or inside cells.
Atefyekta et al. [64] showed that RRP9W4N covalently attached on the elastin-like polypeptide
(ELP) films had anti-biofilm activity toward S. epidermidis, S. aureus, and P. aeruginosa, and moreover,
the stability of covalently attached AMP in human serum was highly increased showing high activity
up to 24 h [18].
Mohid et al. [65] designed two hybrid AMPs, KG18 and VR18, from the parent peptides VG13P
and WR17 [19]. These chimeric peptides display increased and broad-spectrum activity compared to
their parents; moreover, conjugation of ultra-small tungsten disulfide (WS2) QDs to these peptides was
performed to further increase their antimicrobial activity. They proved that these AMP NPs have a
potent antimicrobial e↵ect against both planktonic and biofilm-forming pathogens due to nanoparticles
that enhance membrane lysis and antimicrobial/antibiofilm activities. The combination of non-toxic
ultra-small QDs with potent and selective AMPs represents a promising tool for control of infections
caused by bacterial and fungal pathogens.
Barbosa et al. [66] evaluated the antimicrobial properties of Dhvar-5-chitosan conjugates.
The peptide grafted-chitosan showed significant reduced antimicrobial activity in solution, against all
bacterial species tested, independently of peptide orientation and concentration. In order to further
study the e↵ect of covalently immobilized Dhvar-5 on antibiofilm activity against a biofilm formed by
S. epidermidis, showed an e cient reduction of the total biofilm biomass.
A key point to address is related to the potential of AMP NPs to inhibit the formation and/or
to eradicate the preformed biofilms. For example, novel strategies for e↵ective biofilm inhibition
and/or eradication are highly demanded for the prevention of infections and consequent rejection of
implantable biomaterials. Most studies report on AMPs which are more e↵ective in inhibiting the
early phases of biofilm development rather than in eradicating established biofilms. It is possible that
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prevention of biofilm growth is related to killing of planktonic bacteria prior to attachment, and to
inhibition of bacteria adhesion, which represent critical initial steps in biofilm formation. On the
contrary, eradication of preformed biofilms may be attributed to the ability to disaggregate the matrix
of preformed biofilms, and to di↵use into the deep layers of the biofilm killing bacteria inside the
biofilm. Not many studies report on eradication ability of AMPs. We recently reported an interesting
self-assembled peptide nanostructure decorated on the surface with the Amp WMR which was able to
essentially eradicate already formed biofilm and may represent a novel strategy and may provide an
added value for therapeutic applications [53].
5. In Vivo Models for Biofilms
To broaden in vitro findings, it is important to enforce in vivo mimicking conditions. Models of
infection in vivo and pathogenesis are a continuous interaction between the host and microbes and
between microbes themselves [67]. These interactions are complex and dynamic and make it di cult
to study them in in vitro models.
To validate results in vitro, that could be further translated into higher organisms or clinical
trials, it is necessary to use the right in vivo model [68]. It is very di cult to reproduce the host
environment in in vitro models and for this reason there is a need to use multiple in vivo models
ranging from non-mammalian to mammalian models, mainly rodents [69]. Because of ethical concerns,
the use of in vivo models is now submitted to legal regulations, as it is necessary to consider not only
medical benefits but also animal welfare [70]. This partly explains why researchers are still using
in vitro and in vivo non-mammalian models. Non-mammalian models show advantages such as rapid
development and cheap experiments to perform. Moreover, the genome of most of these organisms
have been sequenced, and it is possible to do genetics both on the bacteria and the host. However,
these non-mammalian models may have limitations such as the growth temperature of pathogens
and are not suitable for studying chronic infections. In the past years, non-mammalian models like
Drosophila melanogaster, among invertebrates, and Danio rerio, among vertebrates, have been adapted to
study host-microbe interactions and immune system responses related to colonization of the intestine
by biofilms [69].
Zebrafish are an emergent model to study human disease. They have a highly developed innate
cellular immune systems that make them a perfect model to study infectious diseases. Currently,
zebrafish are used as a model for imaging and genetics to investigate the molecular and cellular
foundations of host–microbe relationships for the in vivo biofilm studies. Microbiome studies in
zebrafish hosts have concentrated on embryonic and larval stages, when the advantages of this model
are maximized. It is fundamental to understand the interactions between microbe and host to know
the host developmental level when microbes colonize it and know the e↵ects on host ontogeny [71].
Neely et al. [72] have produced a model of bacterial pathogenesis injecting Streptococcus iniae into
zebrafish dorsal muscles. Zebrafish are also susceptible to Streptococcus pyogenes, the human pathogen.
They used genetics and mutagenesis to obtain several attenuated mutants in zebrafish. The success of
the combination Streptococcus–zebrafish makes it a great model for the analysis of infectious disease.
Rawls et al. [73] colonized germ-free zebrafish with P. aeruginosa strains containing mutated genes
for motility obtaining the attenuation of the host innate immune responses. They show the utility
of germ-free zebrafish in determining the comportment and localization of bacteria in vertebrate
intestine and identified the bacterial genes involved on host/microbial interactions. The protective
mechanism against pathogens of probiotic or commensal bacteria in germ-free animal models, remain
poorly understood. Rendueles et al. [74] pre-colonized zebrafish larvae with 37 probiotic bacterial
strains to screen the survival upon Edwardsiella ictaluri infection identifying 3 strong protective strains,
including Vibrio parahaemolyticus and two E. coli strains. They favor the emergence of probiotic
bacteria in zebrafish larvae. The trait of tuberculosis is the formation of granulomas, Stoop et al. [75]
identified new mycobacterial factors involved in the granuloma formation. They utilized the zebrafish
embryo-Mycobacteriummarinummodel to selectedM.marinummutants that did not induce granuloma
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formation. One of the mutants was found to be defective in the espL gene, which is located in the
ESX-1 cluster. This cluster encodes a specialized secretion system important for granuloma formation
and virulence; it is modified in the BCG vaccine strain ofMycobacterium bovis. They concluded that
this screen is useful to identify the genes involved in the initial stages of granuloma formation and to
develop new tuberculosis vaccines.
Amphibian skin continuously comes in contact with diverse aquatic and/or terrestrial microbial
environment and constitute the first line of defense against environmental pathogens working
as an immune organ. The immune functions of frog skin are the maintenance of structural,
physiological, and microbiological barriers; moreover, it permits the interactions across all these
barriers. The cellular and molecular mechanisms that lead to the immune function and defense
against pathogens of amphibian skin are still unknown. To date amphibians have not been considered
to study in vivo biofilms because of their potent innate immuno-defense but, recently, amphibian
immune responses and the contribution of commensal microbes to pathogen defense have been
altered, probably due to environmental changes derived from natural and human factors and new
pathogens infections [76]. In fact, pathogens that normally infect only mammals and humans have
been identified in amphibians. They have caused serious damage to these vertebrates, even death.
In 2016, epidemic meningitis-like disease due to an infection with Elizabethkingia miricola hit Pelophylax
nigromaculatus an edible amphibian in south-central China. Elizabethkingia is a strains of Gram-negative,
non-motile, non–spore-forming bacilli that causes bacteremia and septicemia in immunocompromised
and immunocompetent patients [77]. Mühldorfer et al. reviewed the role of “unusual” Brucella
in amphibians [78] and Ikuta et al. [79] discussed of the first episode of bovine tuberculosis in the
amphibian Lithobates catesbeiana. Previously only nontuberculousmycobacteria infectionswere detected
in amphibians. Environmental pollutants can increase disease risk in wildlife altering the interaction
intestine-microbiota of hosts [80]. Research paradigms from humans, other animals, and plants show
a great influence of environmental microbial ecosystems on the microbiota and health of organisms.
They indicate that a strong link between environmental and internal microbial diversity and good
health exists [81]. These considerations combined with the discovery that pathogens, previously
considered exclusive to mammals, have also been found in amphibians, can push to consider, in the
near future, the use of amphibians as a model for the study of in vivo biofilm. Furthermore, it could be
useful to test the use of AMPs to contrast the diseases derived by these new amphibian pathogens and
then transfer the data obtained to mammals, including humans. The amphibians, such as Xenopus
genus, have a high genomic homology with humans and their genome has been completely sequenced,
in particular X. tropicalis, has a short generation time and a diploid genome, which make it a good
model for genetic studies [82]. Moreover, the development pathways of embryo are similar to those
of mammals, including humans [83]. For these features they are considered, in the scientific world,
an excellent and easy model to replace the use of mammals. Furthermore, it must be considered that
amphibians diverged more recently from amniotes (360 million years ago) than fish (over 400 million
years ago) and thus they could replace zebrafish another non-mammal model widely used in recent
years for biofilm studies. Finally Xenopus can be easily bred in captivity, protocols for its laboratory
breeding are simpler and of a lower cost than those required by rodents.
6. Conclusions
The antibiotic resistant pathogens are increasing and the capacity of new antimicrobial compounds
to control bacterial infections is diminishing. Antimicrobial peptides represent an alternative to classical
antibiotics to control and fight bacterial infections. This review analyses the potentially most suited
features of peptides to combat not only bacteria in their planktonic mode of life but also e↵ective
against already formed biofilms (eradication). In vivo studies could be performed to enhance the
activity of antimicrobial peptides to treat infections caused by multidrug-resistant Gram-positive and
Gram-negative bacteria and the development of suitable models is extremely important. Clearly,
strategies to improve protease susceptibilities of AMPs while still attaining an active nanosystems
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with enhanced proteolytic resistance constitute an added value for therapeutic applications. NPs can
be exploited to favor this proteolic stability and produce supramolecular peptide-based platforms
with potent antibacterial activity, improved functionalities, and enhanced biocompatibility compared
to other antimicrobial molecules. Peptide-based nanosystems could serve also as an important class
of novel antibacterial compounds for the treatment of intracellular microbial infections. To further
improve antibiofilm properties, AMP NPs can be also combined with conventional antibiotics and
allow to decrease the e↵ective concentration of the active molecules, as well as to extend their spectrum
of action, thereby reducing the spread of resistance, which is often linked to monotherapy regimens.
Promisingly, in vivo studies often showed e↵ects that significantly improved clearance of bacterial
isolates from the infection site, regardless of the peptides mode of action including enhancement of
penetration and potential disruption of the stringent stress response.
Thus, it remains a major challenge to translate in vitro findings into in vivo e cacy because often
compounds that show excellent in vitro activity work poorly when tested under in vivo conditions.
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